NeuroXess raises RMB 700 million for its implantable brain-computer interface
Image: NeuroXess / YouTube · video-thumbnail
The Shanghai company closed a Series B on 28 October 2026 to fund a registration trial at nearly 20 hospitals and a factory planned for 10,000 systems a year.
NeuroXess, a brain-computer interface company based in Shanghai, closed a Series B round of RMB 700 million on 28 October 2026, according to TechNode. SDIC Juli, Shenzhen Capital Group and Qinzhi Capital co-led it.
The company reports 65 completed clinical cases. A registration trial, the pivotal study a device maker submits to the regulator for market approval, began in July 2026 at nearly 20 hospitals. NeuroXess says its implantable systems combine flexible electrodes with wireless power and data transmission, and decode movement and speech to control external devices.
The proceeds go to multicentre trials, regulatory submissions, manufacturing capacity and a next-generation product. NeuroXess says it is building a 14,300-square-metre factory with a planned capacity of 10,000 systems a year. The clinical figures and the capacity plan are the company's own statements as relayed by TechNode; the report cites no trial registry entry.
